Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cabazitaxel + abiraterone acetate + prednisone
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous (cabazitaxel), Oral (abiraterone Acetate), Oral (prednisone)
01
Overview
**cabazitaxel + abiraterone acetate + prednisone** is a multi-drug regimen combining a microtubule inhibitor (*cabazitaxel*), a CYP17A1 inhibitor (*abiraterone acetate*), and a synthetic glucocorticoid (*prednisone*). This combination targets metastatic castration-resistant prostate cancer (mCRPC) after progression on docetaxel and abiraterone acetate. - **Cabazitaxel** inhibits microtubule depolymerization, disrupting cell division and inducing death in rapidly proliferating cancer cells. - **Abiraterone acetate** blocks CYP17A1, a crucial enzyme in androgen biosynthesis, suppressing testosterone production that fuels prostate cancer growth. - **Prednisone** is given to reduce mineralocorticoid excess caused by abiraterone acetate and provides additional anti-inflammatory / immunosuppressive effects. Clinical trials show the combination is well-tolerated and achieves higher PSA response rates and radiographic objective responses than monotherapy with either drug alone in heavily pre-treated mCRPC patients[1][3][5].
- Brand names
- Jevtana (cabazitaxel)Zytiga (abiraterone acetate)Deltacortril (prednisone)cabazitaxel + abiraterone acetate + prednisone
- Other names
- cabazitaxel + abiraterone acetate + prednisone
02
Targets
CYP17A1 (Steroid 17-alpha-hydroxylase/C17,20 lyase)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on cabazitaxel + abiraterone acetate + prednisone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cabazitaxel + abiraterone acetate + prednisone.